Skip to main content

About Lauren Carcas

Lauren Carcas, M.D., is a medical oncologist who specializes in breast cancer. She serves as a patient’s primary cancer care physician, diagnosing and staging the disease as well as treating it using chemotherapy, hormonal therapy, biological therapy and targeted therapy. She monitors a patient’s progress, provides supportive care and coordinates treatment provided by other specialists. Dr. Carcas also has extensive training and research experience in the management of other solid malignancies, including lung, colorectal, prostate, bladder, kidney, skin and pancreas, as well as both malignant and benign hematologic conditions. She has conducted numerous clinical trials, most notably in breast cancer, to improve care and outcomes for cancer patients. She has published her clinical results in medical journals and presented at symposiums. She is a member of several professional societies, including the American Society of Clinical Oncology, American Society of Hematology and American College of Physicians. She is fluent in English and Spanish.

Positions

January 2018 - Present Medical Oncologist, Baptist Health South Florida Miami Cancer Institute
to
September 2014 - December 2017 Medical Oncologist, Florida Cancer Care & Florida Cancer Research Institute, LLC.
to
July 2010 - September 2014 Physician, Home Hospice Care, VITAS Innovative Hospice Care
to
June 2010 - June 2011 Chief Medical Resident, Instructor of Medicine, University of Miami ‐ Division of General Internal Medicine, Department of Medicine
to
2010 - 2011 Instructor of Medicine, University of Miami ‐ Division of General Internal Medicine, Department of Medicine
to



Grants

2020 - Present Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291)
AstraZeneca - NCT04305496
Role: Principal Investigator
2019 - Present A Phase III Double-blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple Negative Breast Cancer (TNBC)
AstraZeneca - NCT03997123
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CAPItello-290)
Role: Principal Investigator
2017 - Present MammaPrint, BluePrint, and Full-Genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles (FLEX)
Agendia - NCT03053193
Role: Principal Investigator
2017 - Present Polaris Palbociclib (IBRANCE®) in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study (NIS).
Pfizer - NCT03280303
Role: Principal Investigator
2013 - Present MONALEESA-3 A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor Carcas, Page Rev. April 18, 2022 4 positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment.
Novartis
2013 - Present Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH.
MacroGenics - NCT01828021 and NCT02492711
2016 - 2022 An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptorpositive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
Novartis Pharmaceuticals - NCT02941926
COMPLEEMENT-1
2015 - 2021 A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)
Cascadian Therapeutics - NCT02614794
Role: Sub Investigator
2014 - 2021 Phase II trial of Combination Immunotherapy with nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in high risk HER2+ Breast Cancer patients.
Galena Biopharma
2017 - 2020 Trilaciclib G1T28-04 - Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy.
G1 Therapeutics, Inc. - NCT02978716
Role: Principal Investigator
2016 - 2020 A Phase 2 Study of Poziotinib in Patients with HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC.
Spectrum Pharmaceuticals, Inc - NCT02659514
2016 - 2020 A Phase 3 Open Label, Randomized, Multicenter Study of Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who have Stable Brain Metastases and have been Previously Treated with an Anthracycline, a Taxane, and Capecitabine.
Nektar Therapeutics - NCT02915744
2016 - 2020 TRINITI-1 A Phase I/II, single arm, open-label study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor - Triplet with Ribociclib, AfINItor® and AI posT CDK 4/6 Inhibitor
Novartis Pharmaceuticals - NCT02732119
Role: Sub Investigator
2018 - 2019 Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer
Pfizer
Madeline
Role: Principal Investigator
2017 - 2019 A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer
GlaxoSmithKline - #230774/201973
2010 - 2019 A Registry of Caris Life Sciences® Molecular Intelligence™ Service (Biomarker Assessment Results) Intended for Correlation with Cancer Clinical Outcomes
Caris Life Sciences
2016 - 2018 Randomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE).
Spectrum Pharmaceuticals, Inc - NCT02643420
Role: Sub Investigator
2013 - 2018 Combination Immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2- expressing breast cancer patients to prevent recurrence.
Galena Biopharma
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
2012 - 2017 An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer.
Genentech
2011 - 2017 “PRESENT”: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment
Galena Biopharma - NCT01479244
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)
$
to
Enter a valid date range.

Professional Service and Affiliations

Present Member, American College of Physicians
Present Member, American Medical Association
Present Member, American Society of Clinical Oncology
Present Member, American Society of Hematology
Present Member, Florida Society of Clinical Oncology
to
Enter a valid date range.

Honors and Awards

  • Chief Medical Resident 2010-2011
  • Founder’s Scholarship for Academic Achievement, Samford University 1997-2001
  • Who’s Who Among Students in American Colleges and Universities, 2001
  • Honor Society Memberships: Phi Alpha Theta, Pi Sigma Alpha, Sigma Delta Pi, Pi Gamma Mu, Alpha Lambda Delta

Education

to
July 2011 - August 2014 Fellowship Program - Hematology/Oncology, Jackson Memorial Hospital/University of Miami
to
July 2007 - June 2010 Residency Program - Internal Medicine, Jackson Memorial Hospital/University of Miami
to
August 2002 - December 2006 Doctor of Medicine, M.D., University of Miami ‐ Miller School of Medicine
to
1997 - 2001 Spanish, B.A., Samford University
to
1997 - 2001 International Relations, B.A., Samford University
to


Contact Information

Miami Cancer Institute
8900 N. Kendall Drive
Miami, FL 33176
(786) 596-2000


Articles (5)

Abstracts (3)

Presentations (9)

Videos (3)